

GLOSSARY

A list of all abbreviations and terms appearing in this issue of *Therapy*

5HT	Serotonin	CHD	Coronary heart disease		dehydrogenase
ACAS	Asymptomatic Carotid Atherosclerosis Study	CHF	Congestive heart failure	GAQ	Global Assessment Questions
ACE	Angiotensin-converting enzyme	CHO	Chinese hamster ovary	GFR	Glomerular filtration rate
ACh	Acetylcholine	CI	Confidence interval	GL ₃	Globotriaosylceramide
ACR	American College of Rheumatology	CIA	Collagen-induced arthritis	GM-CSF	Granulocyte-macrophage colony-stimulating factor
ACSs	Acute coronary syndromes	CML	Chronic myelogenous leukemia	gp	Glycoprotein
AdA	Adjuvant arthritis	COPD	Chronic obstructive pulmonary disease	GTP	Guanosine 5'-triphosphate
AFD	Anderson-Fabry disease	COX	Cyclooxygenase	HAQ	Health Assessment Questionnaire
AGAL	α-galactosidase A	CREST	Carotid Revascularization Endarterectomy versus Stent Trial	HCTZ	Hydrochlorothiazide
ALT	Alanine aminotransferase			HLA	Human leukocyte antigen
ANOVA	Analysis of variance	CRP	C-reactive protein	Ho:YAG	Holmium:yttrium-aluminum-garnet
ANS	Autonomic nervous system	CYP	Cytochrome P450		Heart Outcome Prevention Evaluation
APC	Antigen-presenting cell	DAB	Diaminobenzidine	HOPE	Heart Protection Study
ARChEr	ACCULINK for Revascularization of Carotids in High Risk Patients	DC	Dendritic cell	HPS	Hazard ratio
		DCM	Dichloromethane	HR	Intraperitoneally
ARNO	Arimidex-Nolvadex	DMARDs	Disease-modifying antirheumatic drugs	i.p.	Internal carotid artery
ASCO	American Society of Clinical Oncology	DMEM	Dulbecco's modified Eagle's medium	ICA	Intracellular cell adhesion molecule
ASO	Allele-specific oligonucleotide	DMSO	Dimethyl sulfoxide	ICAM	International Collaborative Cancer Group/Breast International Group
ASPIRE	Active Controlled Study of Patients Receiving Infliximab for the Treatment of RA	DRG	Dorsal root ganglion	ICCG/BIG	Inhaled corticosteroid
		EBCTCG	Early Breast Cancer Trialists' Collaborative Group	ICS	Irbesartan in Diabetic Nephropathy Trial
ATAC	Arimidex, Tamoxifen, Alone or in Combination	ECOG	Eastern Cooperative Oncology Group	IDNT	International Exemestane Study
ATCC	American Type Culture Collection	ECST	European Carotid Surgery Trial	IES	Interferon
ATLAS	Adjuvant Tamoxifen: Long Against Shorter	ED	Erectile dysfunction	IFN	Immunoglobulin
ATTOM	Adjuvant Tamoxifen Treatment – Offer More	EDTA	Ethylenediaminetetraacetic acid	Ig	International Index of Erectile Function
ATTRACT	Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy	EF	Erectile Function	IIEF	Inducible NO synthase
		EORTC	European Organization for Research and Treatment of Cancer	iNOS	Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria
AUA	American Urological Association	EPD	Embolic protection device	IRMA	Infusion-related reaction
		ER	Estrogen receptor		Italian Tamoxifen
BBB	Blood-brain barrier	ERK	Extracellular signal-regulated kinase	IRR	Anastrozole
BBUVB	Broadband UVB	ERT	Enzyme-replacement therapy	ITA	Janus kinase
BIG-FEMTA	Breast International Group, Femara-Tamoxifen	ESR	Erythrocyte sedimentation rate	JAK	Juvenile idiopathic arthritis
BP	Blood pressure	ESRD	End-stage renal disease	JIA	Kineret Response Assessment Initiative
BPI	Brief Pain Inventory	FBS	Fetal bovine serum	KREATIVE	Potassium titanyl phosphate:yttrium-aluminum-garnet
BRMs	Biologic response modifiers	FDA	Food and Drug Administration		Low-density lipoprotein
BSF	B-cell stimulating factor			LDL	Lymphocyte function-associated antigen
C ₅	Five or more coughs	FEV ₁	Forced expiratory volume in one second	LFA	Luteinizing hormone-releasing hormone analog
CAD	Coronary artery disease	FGF	Fibroblast growth factor	LHRH-A	Leukocyte inhibitory factor
cAMP	Cyclic adenosine monophosphate	FIRE	Fabry International Research Exchange	LIF	Last observation carried forward
CAS	Carotid artery stenting	FOS	Fabry Outcome Survey	LOCF	Luteal phase
CDR	Complementarity-determining region	FP	Follicular phase		
CEA	Carotid endarterectomy	FVC	Forced vital capacity		
cGMP	Cyclic guanosine monophosphate	GAPDH	Glyceraldehyde-3-phosphate	LP	

LTRA	Leukotriene receptor antagonists	OR	Odds ratio		High Risk for
LVM	Left ventricular mass	OV	Optimized vehicle		Endarterectomy
M6P	Mannose-6-phosphate	PAES	Parodi Anti-Emboli System	SCID	Severe combined immunodeficient
mAb	Monoclonal antibody	PAF	Platelet-activating factor	SD	Standard deviation
MAPK	Mitogen-activated protein kinase	PAI	Plasminogen activator inhibitor	SEP	Sexual Encounter Profile
M-CSF	Macrophage colony-stimulating factor	PASI	Psoriasis area and severity index	SERM	Selective estrogen receptor modulator
MHC	Major histocompatibility complex	PCR	Polymerase chain reaction	SIR	Standardized incidence ratio
MI	Myocardial infarction	PDE	Phosphodiesterase	SLE	Systemic lupus erythematosus
MIRACL	Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering	PDGF	Platelet-derived growth factor	STAT	Signal transducer and activator of transcription
Mm	Myometrium	PG	Prostaglandin	TARGET	Tamoxifen or Arimidex
	postmenopause	Ph	Philadelphia		Randomized Group Efficacy and Tolerability
MPI	Minimal persistent inflammation	PROVE-IT	Pravastatin or Atorvastatin Evaluation and Infection Therapy	TB	Tuberculosis
MRI	Magnetic resonance imaging	PUVA	Long-wave ultraviolet radiation	TC	Total cholesterol
MSSI	Mainz Severity Score Index		photochemotherapy	TCR	T-cell receptor
MTX	Methotrexate	QSART	Quantitative sudomotor axon reflex testing	TEAM	The Tamoxifen and Exemestane Adjuvant Multicentre
NANC	Nonadrenergic–noncholinergic	RA	Rheumatoid arthritis	TEMPO	Trial of Etanercept and MTX with Radiographic Patient Outcomes
NASCET	North American Symptomatic Carotid Endarterectomy Trial	RAAS	Renin–angiotensin–aldosterone system	TGF	Transforming growth factor
		RADIUS	Rheumatoid Arthritis DMARD Intervention and Utilization Study	Th	T-helper
Nd:YAG	Neodymium:yttrium–aluminum–garnet	RAS	Renin–angiotensin system	TKT	Transkaryotic Therapies, Inc.
NFAT	Nuclear factor of activated T-cells	REACT	Randomized European Celecoxib Trial	TNF	Tumor necrosis factor
		REVERSAL	Reversal of Atherosclerosis with Aggressive Lipid Lowering	TNT	Treating to New Targets
NIH	National Institutes of Health			TURP	Transurethral Resection of the Prostate
NK	Neurokinin			TWOC	Time to trial without catheter
NO	Nitric oxide	RFH	Royal Free Hospital	UVA	Ultraviolet A
NP	Normal primer	RMI	Reserpine methiodide	UVB	Ultraviolet B
NSABP	National Surgical Adjuvant Breast and Bowel Project	RMN	Reserpine methonitrate	VCAM	Vascular cell adhesion molecule
NSAIDs	Nonsteroidal anti-inflammatory drugs	RRP	Radical retropubic prostatectomy	VEGF	Vascular endothelial growth factor
		s.c.	Subcutaneous		
OCT	Optimal Cutting Temperature	SAA	Serum amyloid A	WBC	White blood cell
OPG	Osteoprotegerin	SAPPHIRE	Stenting and Angioplasty with Protection in Patients at	WM	White matter